Abstract
Background Demoralization, a syndrome of helplessness, hopelessness, and loss of meaning and chronic pain are common sources of distress in early palliative care. Psilocybin-assisted therapy (PAT) is an emerging intervention with preliminary data suggesting improvements in pain and demoralization. To date, PAT has not been studied among people living with both demoralization and chronic pain nor has it been studied as part of routine multidisciplinary outpatient palliative care.
Objectives We conducted an open-label pilot study assessing the safety, feasibility, and acceptability of PAT delivered with multidisciplinary palliative care support in cancer patients across the illness trajectory living with demoralization and chronic pain.
Methods Participants received a single 25 mg oral dose of psilocybin with preparation, monitoring, and integration provided by a mental health clinician and spiritual health clinician, alongside multidisciplinary palliative care support. Outcomes included safety, feasibility, acceptability, and exploratory self-report measures assessing for demoralization and pain intensity pre- and post-dosing.
Results Eleven participants were enrolled, ten of whom received psilocybin. The intervention was safe and feasible, with no serious adverse events and complete study visit retention among dosed participants. All 10 dosed participants reported the intervention as highly acceptable. Among dosed participants, 70% rated the experience among the five most meaningful and educational of their lives, and 60% among their five most spiritually significant experiences. By study endpoint, 90% no longer met criteria for clinically-significant demoralization syndrome and had pain scores below the trial enrollment threshold.
Conclusions PAT delivered with multidisciplinary palliative care support was safe, feasible, and acceptable in demoralized cancer patients with chronic pain.
Key Message Psilocybin-assisted therapy delivered within multidisciplinary outpatient palliative care was safe, feasible, and acceptable among demoralized cancer patients with chronic pain.
Competing Interest Statement
Ali J. Zarrabi Disclosures: Dr. Zarrabi has received research support from Compass Pathways, Reunion Neuroscience, and the Usona Institute. Boadie W. Dunlop Disclosures: Dr. Dunlop has received research support from Beckley PsyTech, Boehringer Ingelheim, Compass Pathways, LivaNova, NIMH, Reunion Neuroscience, Usona Institute and served as a consultant to Myriad Neuroscience and Otsuka. Barbara O. Rothbaum Disclosures: Dr. Rothbaum has been paid as a consultant by Otsuka, Psychwire, Senseye, MAPS, Lykos, Jazz Pharmaceuticals, GoodCap, Transcend, Penumbra. Roman Palitsky Disclosures: Dr. Palitsky has received research funding from the Tiny Blue Dot Foundation, the Riverstyx Foundation, Shefa, the Common Era Fund, and the Vail Health Foundation. He is a consultant for projects conducted at Harvard Divinity School. Charles Raison: Disclosures: Dr. Raison serves as a consultant for Usona Institute, Eli Lilly, Otsuka and AbbVie and receives research funding from the Tiny Blue Dot Foundation, Vail Health Foundation and ARPA-H. Jessica Maples-Keller Disclosures: Dr. Maples-Keller has received research funding from the Department of Defense, the state of Georgia, and the Wounded Warrior Project, and Multidisciplinary Association of Psychedelic studies, and has received consulting payments from Compass Pathways and Otsuka.
Clinical Trial
NCT05506982
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Emory Institutional Review Board and was registered on Clinicaltrials.gov (NCT05506982). Participants were recruited from November 1, 2022 to January 9, 2024. The study was monitored by the Winship Cancer Institute Data Safety and Monitoring Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Funder Information Declared
